25 XP   0   0   10

Provectus Biopharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Provectus Biopharmaceuticals Inc together

PenkeI guess you are interested in Provectus Biopharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Provectus Biopharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Provectus Biopharmaceuticals Inc

I send you an email if I find something interesting about Provectus Biopharmaceuticals Inc.

Quick analysis of Provectus Biopharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Provectus Biopharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$-0.02
Expected worth in 1 year
$-0.02
How sure are you?
15.0%

+ What do you gain per year?

Total Gains per Share
$0.00
Return On Investment
-0.9%

For what price can you sell your share?

Current Price per Share
$0.18
Expected price per share
$0.1735 - $0.225
How sure are you?
50%

1. Valuation of Provectus Biopharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$0.18

Intrinsic Value Per Share

$0.03 - $0.04

Total Value Per Share

$0.02 - $0.02

2. Growth of Provectus Biopharmaceuticals Inc (5 min.)




Is Provectus Biopharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$7.5m-$5.5m-$1.4m-20.6%

How much money is Provectus Biopharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$792.7k-$1m$222.4k28.1%
Net Profit Margin-229.9%-137.4%--

How much money comes from the company's main activities?

3. Financial Health of Provectus Biopharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#954 / 1031

Most Revenue
#630 / 1031

Most Profit
#235 / 1031

Most Efficient
#678 / 1031

What can you expect buying and holding a share of Provectus Biopharmaceuticals Inc? (5 min.)

Welcome investor! Provectus Biopharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Provectus Biopharmaceuticals Inc.

What can you expect buying and holding a share of Provectus Biopharmaceuticals Inc?

First you should know what it really means to hold a share of Provectus Biopharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Provectus Biopharmaceuticals Inc is $0.1829. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Provectus Biopharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Provectus Biopharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.02. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Provectus Biopharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.00-1.0%0.00-1.0%0.00-1.3%0.00-1.8%-0.01-3.6%
Usd Book Value Change Per Share0.00-0.3%0.00-0.2%0.00-1.3%0.000.5%0.00-0.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.00-0.3%0.00-0.2%0.00-1.3%0.000.5%0.00-0.5%
Usd Price Per Share0.08-0.12-0.06-0.07-0.31-
Price to Earnings Ratio-11.42--15.51--6.05--6.73--7.94-
Price-to-Total Gains Ratio-159.45--84.41--25.38--34.13--55.51-
Price to Book Ratio-4.71--7.10--4.48--3.86-6.19-
Price-to-Total Gains Ratio-159.45--84.41--25.38--34.13--55.51-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.1829
Number of shares5467
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (5467 shares)-2.155.06
Gains per Year (5467 shares)-8.6120.25
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-9-1902010
20-17-2804030
30-26-3706150
40-34-4608170
50-43-55010190
60-52-640121110
70-60-730142130
80-69-820162150
90-77-910182170
100-86-1000202190

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.038.01.02.5%1.040.045.01.2%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%2.018.00.010.0%6.034.00.015.0%24.062.00.027.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%1.00.039.02.5%3.00.083.03.5%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%2.018.00.010.0%6.034.00.015.0%24.062.00.027.9%

Fundamentals of Provectus Biopharmaceuticals Inc

About Provectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections; as well as vertebrate development, wound healing, and tissue regrowth. The company has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Fundamental data was last updated by Penke on 2024-03-12 12:49:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Provectus Biopharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Provectus Biopharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Provectus Biopharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Provectus Biopharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-229.9%+229.9%
TTM-229.9%YOY-137.4%-92.5%
TTM-229.9%5Y-73.5%-156.4%
5Y-73.5%10Y-36.7%-36.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--159.2%+159.2%
TTM-229.9%-202.3%-27.6%
YOY-137.4%-263.0%+125.6%
5Y-73.5%-452.4%+378.9%
10Y-36.7%-589.0%+552.3%
1.1.2. Return on Assets

Shows how efficient Provectus Biopharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Provectus Biopharmaceuticals Inc to the Biotechnology industry mean.
  • -45.9% Return on Assets means that Provectus Biopharmaceuticals Inc generated $-0.46 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Provectus Biopharmaceuticals Inc:

  • The MRQ is -45.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -44.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-45.9%TTM-44.9%-1.0%
TTM-44.9%YOY-37.9%-7.0%
TTM-44.9%5Y-111.0%+66.2%
5Y-111.0%10Y-78.6%-32.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-45.9%-12.5%-33.4%
TTM-44.9%-12.2%-32.7%
YOY-37.9%-11.2%-26.7%
5Y-111.0%-13.3%-97.7%
10Y-78.6%-14.6%-64.0%
1.1.3. Return on Equity

Shows how efficient Provectus Biopharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Provectus Biopharmaceuticals Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Provectus Biopharmaceuticals Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Provectus Biopharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-13.8%+13.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.0%+16.0%
TTM--15.8%+15.8%
YOY--13.9%+13.9%
5Y--18.2%+18.2%
10Y-13.8%-19.1%+5.3%

1.2. Operating Efficiency of Provectus Biopharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Provectus Biopharmaceuticals Inc is operating .

  • Measures how much profit Provectus Biopharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Provectus Biopharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Provectus Biopharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-216.5%+216.5%
TTM-216.5%YOY-133.3%-83.3%
TTM-216.5%5Y-70.0%-146.6%
5Y-70.0%10Y-35.0%-35.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM-216.5%-208.5%-8.0%
YOY-133.3%-280.2%+146.9%
5Y-70.0%-459.9%+389.9%
10Y-35.0%-596.9%+561.9%
1.2.2. Operating Ratio

Measures how efficient Provectus Biopharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Provectus Biopharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.690-2.690
TTM2.690YOY1.583+1.106
TTM2.6905Y0.855+1.835
5Y0.85510Y0.427+0.427
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.817-2.817
TTM2.6903.181-0.491
YOY1.5833.609-2.026
5Y0.8555.554-4.699
10Y0.4277.396-6.969

1.3. Liquidity of Provectus Biopharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Provectus Biopharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.17 means the company has $0.17 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Provectus Biopharmaceuticals Inc:

  • The MRQ is 0.174. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.192. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.174TTM0.192-0.018
TTM0.192YOY0.319-0.128
TTM0.1925Y0.258-0.066
5Y0.25810Y4.659-4.401
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1743.987-3.813
TTM0.1924.440-4.248
YOY0.3195.569-5.250
5Y0.2586.158-5.900
10Y4.6596.492-1.833
1.3.2. Quick Ratio

Measures if Provectus Biopharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Provectus Biopharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Provectus Biopharmaceuticals Inc:

  • The MRQ is 0.000. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.006. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.000TTM0.006-0.006
TTM0.006YOY0.000+0.006
TTM0.0065Y0.116-0.110
5Y0.11610Y4.460-4.344
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0003.653-3.653
TTM0.0064.158-4.152
YOY0.0005.515-5.515
5Y0.1166.012-5.896
10Y4.4606.206-1.746

1.4. Solvency of Provectus Biopharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Provectus Biopharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Provectus Biopharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 5.45 means that Provectus Biopharmaceuticals Inc assets are financed with 544.9% credit (debt) and the remaining percentage (100% - 544.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Provectus Biopharmaceuticals Inc:

  • The MRQ is 5.449. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 4.976. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ5.449TTM4.976+0.473
TTM4.976YOY3.223+1.753
TTM4.9765Y13.385-8.410
5Y13.38510Y7.439+5.946
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4490.336+5.113
TTM4.9760.330+4.646
YOY3.2230.267+2.956
5Y13.3850.367+13.018
10Y7.4390.378+7.061
1.4.2. Debt to Equity Ratio

Measures if Provectus Biopharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Provectus Biopharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Provectus Biopharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y0.127-0.127
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.376-0.376
TTM-0.398-0.398
YOY-0.334-0.334
5Y-0.431-0.431
10Y0.1270.476-0.349

2. Market Valuation of Provectus Biopharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Provectus Biopharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Provectus Biopharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -11.42 means the investor is paying $-11.42 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Provectus Biopharmaceuticals Inc:

  • The EOD is -24.725. Based on the earnings, the company is expensive. -2
  • The MRQ is -11.423. Based on the earnings, the company is expensive. -2
  • The TTM is -15.511. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-24.725MRQ-11.423-13.302
MRQ-11.423TTM-15.511+4.088
TTM-15.511YOY-6.052-9.460
TTM-15.5115Y-6.734-8.777
5Y-6.73410Y-7.937+1.202
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-24.725-2.697-22.028
MRQ-11.423-2.422-9.001
TTM-15.511-2.709-12.802
YOY-6.052-4.116-1.936
5Y-6.734-6.257-0.477
10Y-7.937-6.478-1.459
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Provectus Biopharmaceuticals Inc:

  • The EOD is -24.949. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -11.526. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -18.376. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-24.949MRQ-11.526-13.423
MRQ-11.526TTM-18.376+6.850
TTM-18.376YOY-5.353-13.023
TTM-18.3765Y-8.460-9.916
5Y-8.46010Y-10.831+2.371
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-24.949-3.344-21.605
MRQ-11.526-2.939-8.587
TTM-18.376-3.486-14.890
YOY-5.353-5.592+0.239
5Y-8.460-8.464+0.004
10Y-10.831-8.872-1.959
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Provectus Biopharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -4.71 means the investor is paying $-4.71 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Provectus Biopharmaceuticals Inc:

  • The EOD is -10.205. Based on the equity, the company is expensive. -2
  • The MRQ is -4.715. Based on the equity, the company is expensive. -2
  • The TTM is -7.099. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.205MRQ-4.715-5.490
MRQ-4.715TTM-7.099+2.385
TTM-7.099YOY-4.484-2.616
TTM-7.0995Y-3.857-3.243
5Y-3.85710Y6.191-10.048
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.2052.198-12.403
MRQ-4.7152.042-6.757
TTM-7.0992.121-9.220
YOY-4.4842.907-7.391
5Y-3.8573.682-7.539
10Y6.1914.114+2.077
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Provectus Biopharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0010.000-26%-0.002+340%0.001-157%-0.001+83%
Book Value Per Share---0.018-0.017-7%-0.013-26%-0.036+102%-0.009-48%
Current Ratio--0.1740.192-9%0.319-46%0.258-33%4.659-96%
Debt To Asset Ratio--5.4494.976+10%3.223+69%13.385-59%7.439-27%
Debt To Equity Ratio----0%-0%-0%0.127-100%
Dividend Per Share----0%-0%-0%0.000-100%
Eps---0.002-0.002+2%-0.002+31%-0.003+76%-0.007+256%
Free Cash Flow Per Share---0.002-0.002-10%0.000-78%-0.002+11%-0.005+184%
Free Cash Flow To Equity Per Share--0.0000.000+254%0.001-87%0.000-20%0.001-84%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.975+3%
Intrinsic Value_10Y_max--0.042--------
Intrinsic Value_10Y_min--0.033--------
Intrinsic Value_1Y_max---0.004--------
Intrinsic Value_1Y_min---0.004--------
Intrinsic Value_3Y_max---0.006--------
Intrinsic Value_3Y_min---0.006--------
Intrinsic Value_5Y_max--0.000--------
Intrinsic Value_5Y_min---0.001--------
Market Cap76730570.874+54%35449619.05649388228.418-28%23891776.989+48%30207681.028+17%131915541.739-73%
Net Profit Margin----2.2990%-1.3740%-0.7350%-0.3670%
Operating Margin----2.1650%-1.3330%-0.7000%-0.3500%
Operating Ratio---2.690-100%1.583-100%0.855-100%0.427-100%
Pb Ratio-10.205-116%-4.715-7.099+51%-4.484-5%-3.857-18%6.191-176%
Pe Ratio-24.725-116%-11.423-15.511+36%-6.052-47%-6.734-41%-7.937-31%
Price Per Share0.183+54%0.0850.118-28%0.057+48%0.072+17%0.314-73%
Price To Free Cash Flow Ratio-24.949-116%-11.526-18.376+59%-5.353-54%-8.460-27%-10.831-6%
Price To Total Gains Ratio-345.135-116%-159.453-84.409-47%-25.385-84%-34.129-79%-55.512-65%
Quick Ratio--0.0000.006-98%0.000-71%0.116-100%4.460-100%
Return On Assets---0.459-0.449-2%-0.379-17%-1.110+142%-0.786+71%
Return On Equity----0%-0%-0%-0.1380%
Total Gains Per Share---0.0010.000-26%-0.002+340%0.001-157%-0.001+82%
Usd Book Value---7519204.000-7011589.500-7%-5565463.750-26%-15179673.550+102%-3919775.250-48%
Usd Book Value Change Per Share---0.0010.000-26%-0.002+340%0.001-157%-0.001+83%
Usd Book Value Per Share---0.018-0.017-7%-0.013-26%-0.036+102%-0.009-48%
Usd Dividend Per Share----0%-0%-0%0.000-100%
Usd Eps---0.002-0.002+2%-0.002+31%-0.003+76%-0.007+256%
Usd Free Cash Flow---768874.000-691389.250-10%-166176.250-78%-856711.050+11%-2132557.200+177%
Usd Free Cash Flow Per Share---0.002-0.002-10%0.000-78%-0.002+11%-0.005+184%
Usd Free Cash Flow To Equity Per Share--0.0000.000+254%0.001-87%0.000-20%0.001-84%
Usd Market Cap76730570.874+54%35449619.05649388228.418-28%23891776.989+48%30207681.028+17%131915541.739-73%
Usd Price Per Share0.183+54%0.0850.118-28%0.057+48%0.072+17%0.314-73%
Usd Profit---775839.000-792752.000+2%-1015193.250+31%-1366046.850+76%-2649404.400+241%
Usd Revenue---91716.750-100%46901.250-100%27723.600-100%13861.800-100%
Usd Total Gains Per Share---0.0010.000-26%-0.002+340%0.001-157%-0.001+82%
 EOD+6 -2MRQTTM+7 -22YOY+14 -155Y+18 -1110Y+19 -14

3.2. Fundamental Score

Let's check the fundamental score of Provectus Biopharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-24.725
Price to Book Ratio (EOD)Between0-1-10.205
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than10.174
Debt to Asset Ratio (MRQ)Less than15.449
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.459
Total1/10 (10.0%)

3.3. Technical Score

Let's check the technical score of Provectus Biopharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.625
Ma 20Greater thanMa 500.194
Ma 50Greater thanMa 1000.154
Ma 100Greater thanMa 2000.136
OpenGreater thanClose0.200
Total5/5 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets1,690
Total Liabilities9,209
Total Stockholder Equity-7,519
 As reported
Total Liabilities 9,209
Total Stockholder Equity+ -7,519
Total Assets = 1,690

Assets

Total Assets1,690
Total Current Assets1,592
Long-term Assets98
Total Current Assets
Cash And Cash Equivalents 367
Net Receivables 1
Other Current Assets 181
Total Current Assets  (as reported)1,592
Total Current Assets  (calculated)549
+/- 1,043
Long-term Assets
Property Plant Equipment 98
Long-term Assets  (as reported)98
Long-term Assets  (calculated)98
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities9,172
Long-term Liabilities38
Total Stockholder Equity-7,519
Total Current Liabilities
Short Long Term Debt 3,071
Accounts payable 1,785
Total Current Liabilities  (as reported)9,172
Total Current Liabilities  (calculated)4,856
+/- 4,316
Long-term Liabilities
Long-term Liabilities  (as reported)38
Long-term Liabilities  (calculated)0
+/- 38
Total Stockholder Equity
Total Stockholder Equity (as reported)-7,519
Total Stockholder Equity (calculated)0
+/- 7,519
Other
Capital Stock442
Common Stock Shares Outstanding 419,522
Net Debt 2,703
Net Invested Capital -4,471
Net Working Capital -7,579
Property Plant and Equipment Gross 207



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-31
> Total Assets 
0
0
0
0
0
0
0
0
0
5
5
21,155
20,283
19,781
19,562
19,827
19,610
19,283
11,305
11,196
10,941
11,593
10,818
17,319
16,272
15,432
15,583
16,325
16,491
15,535
16,181
15,711
13,669
12,868
12,357
10,518
9,083
11,187
10,960
10,234
18,596
19,383
16,556
14,403
18,595
20,467
16,669
13,350
10,445
9,466
7,011
6,204
9,272
9,373
12,780
20,008
20,791
22,099
21,648
26,184
22,771
31,242
26,604
20,440
16,019
10,829
10,686
5,611
4,510
4,929
3,852
3,436
3,058
3,526
2,422
1,988
3,692
2,718
1,564
1,477
820
1,839
1,345
589
771
466
600
3,513
2,756
2,443
2,050
2,037
1,720
1,687
1,690
1,6901,6871,7202,0372,0502,4432,7563,5136004667715891,3451,8398201,4771,5642,7183,6921,9882,4223,5263,0583,4363,8524,9294,5105,61110,68610,82916,01920,44026,60431,24222,77126,18421,64822,09920,79120,00812,7809,3739,2726,2047,0119,46610,44513,35016,66920,46718,59514,40316,55619,38318,59610,23410,96011,1879,08310,51812,35712,86813,66915,71116,18115,53516,49116,32515,58315,43216,27217,31910,81811,59310,94111,19611,30519,28319,61019,82719,56219,78120,28321,15555000000000
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,484
10,855
0
0
0
0
0
0
0
0
15,696
16,649
18,126
17,774
19,103
15,861
24,503
19,950
14,720
10,448
5,408
5,415
1,826
887
1,473
534
958
745
1,379
442
1,017
2,715
1,859
894
996
528
1,630
1,158
424
629
347
507
3,442
2,712
2,279
1,899
1,899
1,596
1,575
1,592
1,5921,5751,5961,8991,8992,2792,7123,4425073476294241,1581,6305289968941,8592,7151,0174421,3797459585341,4738871,8265,4155,40810,44814,72019,95024,50315,86119,10317,77418,12616,64915,6960000000010,85514,484000000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
438
233
339
352
213
5
449
2,796
1,499
3,813
3,780
3,237
11,441
12,509
10,044
8,086
12,401
14,390
10,813
7,706
4,900
4,072
1,842
1,222
4,318
4,636
8,254
15,696
16,649
18,126
17,774
17,392
14,171
23,117
18,884
14,179
9,761
4,891
5,178
1,166
437
1,128
208
106
244
131
232
51
1,768
1,324
435
591
214
1,483
987
97
350
47
254
683
174
84
67
22
34
176
367
3671763422678417468325447350979871,4832145914351,3241,768512321312441062081,1284371,1665,1784,8919,76114,17918,88423,11714,17117,39217,77418,12616,64915,6968,2544,6364,3181,2221,8424,0724,9007,70610,81314,39012,4018,08610,04412,50911,4413,2373,7803,8131,4992,79644952133523392334380000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,029
6,568
7,302
6,908
5,202
4,806
4,003
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000000004,0034,8065,2026,9087,3026,5687,0290000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
733
467
200
0
500
350
200
50
300
200
100
0
452
200
975
2
595
604
293
290
55
74
4
6
4
4
5
1
5
3
3
1
0
1
1
1
1110133515446474552902936045952975200452010020030050200350500020046773300000000000000000000000000000000000000000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
35
108
105
245
599
484
199
737
498
378
222
41
68
133
318
370
174
162
42
18
100
73
46
64
51
83
43
19
0
329
218
25
0
47
94
42
0
54
72
16
0
141
93
45
0
0
0
0
978
1,224
1,186
1,066
41
337
317
187
361
251
245
325
400
301
274
208
370
272
242
169
350
240
4
165
323
275
294
1
2,424
2,307
1,948
1,644
1,410
1,561
1,398
181
1811,3981,5611,4101,6441,9482,3072,42412942753231654240350169242272370208274301400325245251361187317337411,0661,1861,2249780000459314101672540429447025218329019438351644673100184216217437031813368412223784987371994845992451051083500000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,983
5,814
0
0
0
0
0
0
0
0
4,312
4,142
3,973
3,874
7,081
6,910
6,739
6,654
5,720
5,571
5,421
5,270
3,785
3,623
3,456
3,319
2,478
2,313
2,147
1,981
972
1,048
859
670
481
292
209
187
166
142
119
94
71
44
165
151
138
125
111
98
981111251381511654471941191421661872092924816708591,0489721,9812,1472,3132,4783,3193,4563,6233,7855,2705,4215,5715,7206,6546,7396,9107,0813,8743,9734,1424,312000000005,8145,983000000000000000000000000000000000000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
471
391
212
162
121
68
29
5
0
11
11
11
12
20
19
18
30
50
48
45
43
41
38
36
34
31
29
27
30
28
25
24
21
19
24
22
20
35
33
31
30
28
27
32
30
28
27
96
92
89
86
89
85
82
78
75
72
69
63
85
87
83
80
76
72
69
65
62
58
55
209
48
45
41
38
94
71
44
165
151
138
125
111
98
98111125138151165447194384145482095558626569727680838785636972757882858986899296272830322728303133352022241921242528302729313436384143454850301819201211111105296812116221239147100000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,378
3,378
3,378
3,458
2,012
683
683
683
1,016
1,024
1,032
1,040
366
372
377
382
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000003823773723661,0401,0321,0241,0166836836832,0123,4583,3783,3783,37800000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
19,904
19,617
19,330
19,043
18,756
18,469
18,182
10,462
10,295
10,127
9,959
9,791
9,624
9,456
9,288
9,120
8,953
8,785
8,617
8,450
8,281
8,113
7,946
7,778
7,610
7,443
7,275
7,107
6,940
6,771
6,604
6,436
6,269
6,101
5,933
5,765
5,597
5,429
5,262
5,094
4,925
4,758
4,590
4,422
4,255
4,087
3,919
3,751
3,584
3,416
3,248
3,080
2,913
2,745
2,577
2,409
2,241
2,074
1,906
1,738
1,570
1,403
1,235
1,067
899
731
564
396
228
60
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000602283965647318991,0671,2351,4031,5701,7381,9062,0742,2412,4092,5772,7452,9133,0803,2483,4163,5843,7513,9194,0874,2554,4224,5904,7584,9255,0945,2625,4295,5975,7655,9336,1016,2696,4366,6046,7716,9407,1077,2757,4437,6107,7787,9468,1138,2818,4508,6178,7858,9539,1209,2889,4569,6249,7919,95910,12710,29510,46218,18218,46918,75619,04319,33019,61719,90400000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
19,931
19,644
19,357
19,070
18,783
18,496
18,209
10,489
10,593
10,403
10,680
10,337
10,360
9,892
9,378
9,172
8,984
8,812
8,644
8,477
8,308
8,140
7,973
7,805
7,637
7,470
7,302
7,134
6,967
6,798
6,631
6,463
6,296
6,128
5,959
5,792
5,624
5,456
5,289
5,122
4,952
4,785
4,617
4,449
4,282
4,114
3,946
3,778
6,989
6,821
6,653
6,565
5,635
5,489
5,343
5,196
3,713
3,554
3,393
3,233
2,391
827
833
838
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000008388338272,3913,2333,3933,5543,7135,1965,3435,4895,6356,5656,6536,8216,9893,7783,9464,1144,2824,4494,6174,7854,9525,1225,2895,4565,6245,7925,9596,1286,2966,4636,6316,7986,9677,1347,3027,4707,6377,8057,9738,1408,3088,4778,6448,8128,9849,1729,3789,89210,36010,33710,68010,40310,59310,48918,20918,49618,78319,07019,35719,64419,93100000000000
> Total Liabilities 
0
0
0
0
0
0
3
4
4
30
49
1,166
1,168
1,378
1,944
1,786
1,904
2,095
1,887
2,034
2,290
2,495
2,410
2,932
1,013
858
891
803
355
474
731
880
347
363
666
462
651
1,022
834
827
528
783
1,023
3,703
6,876
5,693
4,502
3,330
4,257
4,601
3,587
1,811
3,815
3,026
4,057
13,380
6,271
2,119
2,108
994
1,075
995
2,075
4,123
1,835
1,689
5,376
2,142
5,431
9,144
11,161
13,455
15,554
17,226
17,711
19,406
22,497
23,684
24,152
25,549
26,686
29,316
30,059
30,796
32,387
3,077
3,549
7,701
7,825
8,590
8,909
8,266
8,722
8,983
9,209
9,2098,9838,7228,2668,9098,5907,8257,7013,5493,07732,38730,79630,05929,31626,68625,54924,15223,68422,49719,40617,71117,22615,55413,45511,1619,1445,4312,1425,3761,6891,8354,1232,0759951,0759942,1082,1196,27113,3804,0573,0263,8151,8113,5874,6014,2573,3304,5025,6936,8763,7031,0237835288278341,0226514626663633478807314743558038918581,0132,9322,4102,4952,2902,0341,8872,0951,9041,7861,9441,3781,1681,1664930443000000
   > Total Current Liabilities 
0
0
0
0
0
0
3
4
4
30
49
177
138
332
842
1,637
1,755
1,946
1,602
1,451
1,663
1,872
2,009
2,609
1,013
858
891
803
355
474
731
880
347
363
666
462
651
1,022
834
827
528
783
1,023
1,350
719
653
490
263
927
1,723
1,955
511
295
414
542
513
835
816
881
848
1,022
988
2,075
4,123
1,835
1,689
5,376
2,142
5,431
3,594
4,061
3,999
4,642
4,864
3,250
4,102
2,871
2,671
2,372
3,023
3,987
29,190
29,954
30,712
32,365
3,077
3,549
7,701
7,825
8,494
8,824
8,192
8,660
8,934
9,172
9,1728,9348,6608,1928,8248,4947,8257,7013,5493,07732,36530,71229,95429,1903,9873,0232,3722,6712,8714,1023,2504,8644,6423,9994,0613,5945,4312,1425,3761,6891,8354,1232,0759881,0228488818168355135424142955111,9551,7239272634906537191,3501,0237835288278341,0226514626663633478807314743558038918581,0132,6092,0091,8721,6631,4511,6021,9461,7551,6378423321381774930443000000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,500
5,550
7,100
9,456
10,912
12,362
0
0
73
0
0
500
1,000
15,895
16,520
16,622
17,847
0
0
0
0
0
0
0
2,533
2,751
0
02,7512,533000000017,84716,62216,52015,8951,00050000730012,36210,9129,4567,1005,5502,50000000000000000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,500
5,550
7,100
9,456
10,912
12,362
0
0
73
0
0
500
1,000
22,665
23,290
23,628
24,791
127
268
1,698
1,665
2,153
2,592
2,067
2,533
2,751
3,071
3,0712,7512,5332,0672,5922,1531,6651,69826812724,79123,62823,29022,6651,00050000730012,36210,9129,4567,1005,5502,50000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
4
4
25
43
99
53
229
304
101
142
80
158
154
151
147
88
90
17
104
39
65
35
83
33
455
134
144
123
267
135
237
111
220
202
67
95
418
244
484
258
101
313
189
281
243
50
65
202
513
835
816
881
848
1,022
988
2,065
2,273
1,835
1,689
2,033
2,142
2,931
3,594
4,061
3,999
4,642
4,864
3,250
4,102
2,798
2,596
2,295
2,446
2,907
1,458
11,721
12,003
12,331
2,863
1,260
1,287
1,597
1,894
1,941
2,094
4,705
4,878
1,785
1,7854,8784,7052,0941,9411,8941,5971,2871,2602,86312,33112,00311,7211,4582,9072,4462,2952,5962,7984,1023,2504,8644,6423,9994,0613,5942,9312,1422,0331,6891,8352,2732,0659881,0228488818168355132026550243281189313101258484244418956720222011123713526712314413445533833565391041790881471511541588014210130422953994325440000000
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
78
85
103
538
510
446
533
428
206
397
354
432
1,963
210
267
350
373
320
391
698
425
213
219
543
195
516
785
723
607
326
716
928
932
475
5,208
4,244
162
614
1,534
1,674
268
245
349
340
164
110
336
403
407
370
470
10
1,850
437
916
3,342
222
160
320
509
729
960
1,364
790
0
73
75
76
76
80
1,576
1,713
2,087
2,187
214
150
2,650
2,312
1,991
1,676
1,511
1,423
1,305
0
01,3051,4231,5111,6761,9912,3122,6501502142,1872,0871,7131,576807676757307901,3649607295093201602223,3429164371,850104703704074033361101643403492452681,6741,5346141624,2445,2084759329287163266077237855161955432192134256983913203733502672101,963432354397206428533446510538103857800000000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,867
5,436
1,303
1,227
147
53
7
0
0
0
0
0
0
0
5,550
7,100
9,456
10,912
12,362
14,461
15,303
19,625
21,012
21,781
22,526
22,699
126
105
84
22
0
0
0
0
96
85
73
62
50
38
3850627385960000228410512622,69922,52621,78121,01219,62515,30314,46112,36210,9129,4567,1005,55000000007531471,2271,3035,43612,8670000000000000000000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,550
7,100
9,456
10,912
12,362
13,362
13,932
17,732
11,887
12,297
12,997
12,697
39
39
0
0
0
0
0
0
0
0
0
0
0
0
000000000000393912,69712,99712,29711,88717,73213,93213,36212,36210,9129,4567,1005,550000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,353
6,157
5,039
4,012
3,067
3,330
2,878
1,632
1,300
3,520
2,612
3,515
12,866
5,436
1,303
1,228
146
53
7
0
0
0
0
0
0
0
3,000
4,000
5,000
5,750
0
1,099
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,09905,7505,0004,0003,00000000007531461,2281,3035,43612,8663,5152,6123,5201,3001,6322,8783,3303,0674,0125,0396,1572,3530000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
0
0
0
0
0
0
0
0
19,989
19,115
18,403
17,618
18,041
17,706
17,188
9,418
9,162
8,651
9,098
8,408
14,387
15,259
14,574
14,692
15,522
16,136
15,061
15,450
14,831
13,322
12,505
11,691
10,056
8,432
10,165
10,126
9,407
18,068
18,600
15,533
10,700
11,719
14,775
12,166
10,020
6,188
4,865
3,424
4,393
5,457
6,347
8,723
6,629
14,520
19,980
19,539
25,190
21,696
30,247
24,529
16,317
14,184
9,140
5,310
3,469
-920
-4,215
-7,309
-10,019
-12,496
-13,700
-15,289
-17,417
-18,804
-20,965
-22,588
-24,072
-25,866
-27,477
-28,714
-30,206
-31,616
-2,611
-2,949
-4,187
-5,069
-6,147
-6,859
-6,229
-7,002
-7,297
-7,519
-7,519-7,297-7,002-6,229-6,859-6,147-5,069-4,187-2,949-2,611-31,616-30,206-28,714-27,477-25,866-24,072-22,588-20,965-18,804-17,417-15,289-13,700-12,496-10,019-7,309-4,215-9203,4695,3109,14014,18416,31724,52930,24721,69625,19019,53919,98014,5206,6298,7236,3475,4574,3933,4244,8656,18810,02012,16614,77511,71910,70015,53318,60018,0689,40710,12610,1658,43210,05611,69112,50513,32214,83115,45015,06116,13615,52214,69214,57415,25914,3878,4089,0988,6519,1629,41817,18817,70618,04117,61818,40319,11519,98900000000000
   Retained Earnings -252,027-251,251-250,416-249,589-248,856-248,143-247,065-246,034-244,795-243,744-242,164-240,494-238,823-237,259-235,644-233,817-232,262-230,441-228,264-226,894-224,706-223,097-221,641-218,741-216,019-212,908-209,613-205,223-200,223-194,347-189,302-180,796-171,144-165,364-160,819-156,294-157,110-153,362-152,718-146,05100000000-102,333-95,890000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
110,552
114,385
0
0
0
0
0
0
0
0
152,520
167,065
173,164
176,469
181,299
182,329
195,406
195,469
196,908
203,274
203,274
205,289
208,328
208,322
208,322
208,340
208,351
208,766
209,014
209,034
209,092
209,097
209,116
209,310
209,379
209,421
209,422
209,745
209,923
210,178
240,742
0
0
0
0
0
0
243,008
243,548
0
0243,548243,008000000240,742210,178209,923209,745209,422209,421209,379209,310209,116209,097209,092209,034209,014208,766208,351208,340208,322208,322208,328205,289203,274203,274196,908195,469195,406182,329181,299176,469173,164167,065152,52000000000114,385110,552000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-2,965
Operating Income-2,965-2,965
 
Operating Expense (+$)
Research Development1,655
Selling General Administrative1,925
Selling And Marketing Expenses-
Operating Expense2,9653,580
 
Net Interest Income (+$)
Interest Income-
Interest Expense-206
Other Finance Cost-0
Net Interest Income-206
 
Pretax Income (+$)
Operating Income-2,965
Net Interest Income-206
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-3,171-2,965
EBIT - interestExpense = -206
-3,171
-2,965
Interest Expense206
Earnings Before Interest and Taxes (EBIT)--2,965
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-3,171
Tax Provision--
Net Income From Continuing Ops-3,171-3,171
Net Income-3,171
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-206
 

Technical Analysis of Provectus Biopharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Provectus Biopharmaceuticals Inc. The general trend of Provectus Biopharmaceuticals Inc is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Provectus Biopharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Provectus Biopharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.223 < 0.225.

The bearish price targets are: 0.1895 > 0.1749 > 0.1735.

Tweet this
Provectus Biopharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Provectus Biopharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Provectus Biopharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Provectus Biopharmaceuticals Inc. The current macd is 0.01158239.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Provectus Biopharmaceuticals Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Provectus Biopharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Provectus Biopharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Provectus Biopharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartProvectus Biopharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Provectus Biopharmaceuticals Inc. The current adx is 27.25.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Provectus Biopharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Provectus Biopharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Provectus Biopharmaceuticals Inc. The current sar is 0.21250164.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Provectus Biopharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Provectus Biopharmaceuticals Inc. The current rsi is 50.62. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Provectus Biopharmaceuticals Inc Daily Relative Strength Index (RSI) ChartProvectus Biopharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Provectus Biopharmaceuticals Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Provectus Biopharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Provectus Biopharmaceuticals Inc Daily Stochastic Oscillator ChartProvectus Biopharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Provectus Biopharmaceuticals Inc. The current cci is -29.15172031.

Provectus Biopharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartProvectus Biopharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Provectus Biopharmaceuticals Inc. The current cmo is -12.88713131.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Provectus Biopharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartProvectus Biopharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Provectus Biopharmaceuticals Inc. The current willr is -87.8914405.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Provectus Biopharmaceuticals Inc Daily Williams %R ChartProvectus Biopharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Provectus Biopharmaceuticals Inc. The current atr is 0.0170955.

Provectus Biopharmaceuticals Inc Daily Average True Range (ATR) ChartProvectus Biopharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Provectus Biopharmaceuticals Inc. The current obv is 3,970,251.

Provectus Biopharmaceuticals Inc Daily On-Balance Volume (OBV) ChartProvectus Biopharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Provectus Biopharmaceuticals Inc. The current mfi is 54.67.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Provectus Biopharmaceuticals Inc Daily Money Flow Index (MFI) ChartProvectus Biopharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Provectus Biopharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-26MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Provectus Biopharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Provectus Biopharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.625
Ma 20Greater thanMa 500.194
Ma 50Greater thanMa 1000.154
Ma 100Greater thanMa 2000.136
OpenGreater thanClose0.200
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Provectus Biopharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Provectus Biopharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Provectus Biopharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Provectus Biopharmaceuticals Inc

I send you an email if I find something interesting about Provectus Biopharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Provectus Biopharmaceuticals Inc.

Receive notifications about Provectus Biopharmaceuticals Inc in your mailbox!